Cargando…

Development of a core minimum data set to advance real-world evidence generation for uterine fibroids treatment technologies

OBJECTIVES: The accumulation of data through a prospective, multicenter coordinated registry network (CRN) is a robust and cost-effective way to gather real-world evidence on the performance of uterine fibroids treatment technologies for device-based and intervention-based studies. To develop the CR...

Descripción completa

Detalles Bibliográficos
Autores principales: Baird, Courtney E, Myers, Evan, Jacoby, Vanessa, Gressler, Laura Elisabeth, Venable, Sateria, O'Neill, Allison, Price, Veronica, Lee, Angie, Roberts, Jason, Andrews, Sharon, Sedrakyan, Art, Marinac-Dabic, Danica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660574/
https://www.ncbi.nlm.nih.gov/pubmed/36393887
http://dx.doi.org/10.1136/bmjsit-2021-000094
_version_ 1784830421383512064
author Baird, Courtney E
Myers, Evan
Jacoby, Vanessa
Gressler, Laura Elisabeth
Venable, Sateria
O'Neill, Allison
Price, Veronica
Lee, Angie
Roberts, Jason
Andrews, Sharon
Sedrakyan, Art
Marinac-Dabic, Danica
author_facet Baird, Courtney E
Myers, Evan
Jacoby, Vanessa
Gressler, Laura Elisabeth
Venable, Sateria
O'Neill, Allison
Price, Veronica
Lee, Angie
Roberts, Jason
Andrews, Sharon
Sedrakyan, Art
Marinac-Dabic, Danica
author_sort Baird, Courtney E
collection PubMed
description OBJECTIVES: The accumulation of data through a prospective, multicenter coordinated registry network (CRN) is a robust and cost-effective way to gather real-world evidence on the performance of uterine fibroids treatment technologies for device-based and intervention-based studies. To develop the CRN, a group of uterine fibroids experts, consisting of representatives from professional societies, the US Food and Drug Administration, academia, industry, and the patient community, was convened to discuss the role and feasibility of the CRN and to identify the core data elements needed to assess uterine fibroid treatment technologies. DESIGN: A Delphi method approach was employed to achieve consensus on a core minimum data set for the CRN. A series of surveys were sent to the panel and answered by each expert anonymously and individually. Results from the surveys were collected, collated, and analyzed by a study design team from Weill Cornell Medicine. Questions for the next round were based on the analysis process and discussed with group members via a conference call. This process was repeated twice over a 3-month time period until consensus was achieved. RESULTS: Twenty-nine experts participated in the Delphi surveys, which began with an initial list of 200 data elements. The working group reached final consensus on 97 data elements capturing patient medical history, imaging data, procedure-related data, post-procedure data, and long-term follow-up data. CONCLUSIONS: The CRN successfully convened an expert panel on uterine fibroids treatment technologies and used the Delphi method to produce a consensus-based core set of data elements. These identified data elements include important outcomes related to efficacy and safety and thus, influence patient, provider, and regulatory decision-making about treatments for uterine fibroids. Finally, the core data elements provide the foundation of the infrastructure needed for the CRN that will allow for the comparative study of uterine fibroid treatment devices and technologies.
format Online
Article
Text
id pubmed-9660574
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-96605742022-11-15 Development of a core minimum data set to advance real-world evidence generation for uterine fibroids treatment technologies Baird, Courtney E Myers, Evan Jacoby, Vanessa Gressler, Laura Elisabeth Venable, Sateria O'Neill, Allison Price, Veronica Lee, Angie Roberts, Jason Andrews, Sharon Sedrakyan, Art Marinac-Dabic, Danica BMJ Surg Interv Health Technol Original Research OBJECTIVES: The accumulation of data through a prospective, multicenter coordinated registry network (CRN) is a robust and cost-effective way to gather real-world evidence on the performance of uterine fibroids treatment technologies for device-based and intervention-based studies. To develop the CRN, a group of uterine fibroids experts, consisting of representatives from professional societies, the US Food and Drug Administration, academia, industry, and the patient community, was convened to discuss the role and feasibility of the CRN and to identify the core data elements needed to assess uterine fibroid treatment technologies. DESIGN: A Delphi method approach was employed to achieve consensus on a core minimum data set for the CRN. A series of surveys were sent to the panel and answered by each expert anonymously and individually. Results from the surveys were collected, collated, and analyzed by a study design team from Weill Cornell Medicine. Questions for the next round were based on the analysis process and discussed with group members via a conference call. This process was repeated twice over a 3-month time period until consensus was achieved. RESULTS: Twenty-nine experts participated in the Delphi surveys, which began with an initial list of 200 data elements. The working group reached final consensus on 97 data elements capturing patient medical history, imaging data, procedure-related data, post-procedure data, and long-term follow-up data. CONCLUSIONS: The CRN successfully convened an expert panel on uterine fibroids treatment technologies and used the Delphi method to produce a consensus-based core set of data elements. These identified data elements include important outcomes related to efficacy and safety and thus, influence patient, provider, and regulatory decision-making about treatments for uterine fibroids. Finally, the core data elements provide the foundation of the infrastructure needed for the CRN that will allow for the comparative study of uterine fibroid treatment devices and technologies. BMJ Publishing Group 2022-11-11 /pmc/articles/PMC9660574/ /pubmed/36393887 http://dx.doi.org/10.1136/bmjsit-2021-000094 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Baird, Courtney E
Myers, Evan
Jacoby, Vanessa
Gressler, Laura Elisabeth
Venable, Sateria
O'Neill, Allison
Price, Veronica
Lee, Angie
Roberts, Jason
Andrews, Sharon
Sedrakyan, Art
Marinac-Dabic, Danica
Development of a core minimum data set to advance real-world evidence generation for uterine fibroids treatment technologies
title Development of a core minimum data set to advance real-world evidence generation for uterine fibroids treatment technologies
title_full Development of a core minimum data set to advance real-world evidence generation for uterine fibroids treatment technologies
title_fullStr Development of a core minimum data set to advance real-world evidence generation for uterine fibroids treatment technologies
title_full_unstemmed Development of a core minimum data set to advance real-world evidence generation for uterine fibroids treatment technologies
title_short Development of a core minimum data set to advance real-world evidence generation for uterine fibroids treatment technologies
title_sort development of a core minimum data set to advance real-world evidence generation for uterine fibroids treatment technologies
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660574/
https://www.ncbi.nlm.nih.gov/pubmed/36393887
http://dx.doi.org/10.1136/bmjsit-2021-000094
work_keys_str_mv AT bairdcourtneye developmentofacoreminimumdatasettoadvancerealworldevidencegenerationforuterinefibroidstreatmenttechnologies
AT myersevan developmentofacoreminimumdatasettoadvancerealworldevidencegenerationforuterinefibroidstreatmenttechnologies
AT jacobyvanessa developmentofacoreminimumdatasettoadvancerealworldevidencegenerationforuterinefibroidstreatmenttechnologies
AT gresslerlauraelisabeth developmentofacoreminimumdatasettoadvancerealworldevidencegenerationforuterinefibroidstreatmenttechnologies
AT venablesateria developmentofacoreminimumdatasettoadvancerealworldevidencegenerationforuterinefibroidstreatmenttechnologies
AT oneillallison developmentofacoreminimumdatasettoadvancerealworldevidencegenerationforuterinefibroidstreatmenttechnologies
AT priceveronica developmentofacoreminimumdatasettoadvancerealworldevidencegenerationforuterinefibroidstreatmenttechnologies
AT leeangie developmentofacoreminimumdatasettoadvancerealworldevidencegenerationforuterinefibroidstreatmenttechnologies
AT robertsjason developmentofacoreminimumdatasettoadvancerealworldevidencegenerationforuterinefibroidstreatmenttechnologies
AT andrewssharon developmentofacoreminimumdatasettoadvancerealworldevidencegenerationforuterinefibroidstreatmenttechnologies
AT sedrakyanart developmentofacoreminimumdatasettoadvancerealworldevidencegenerationforuterinefibroidstreatmenttechnologies
AT marinacdabicdanica developmentofacoreminimumdatasettoadvancerealworldevidencegenerationforuterinefibroidstreatmenttechnologies